Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
2(40%)
Results Posted
0%(0 trials)

Phase Distribution

Ph not_applicable
3
60%
Ph phase_1
2
40%

Phase Distribution

2

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
2(40.0%)
N/ANon-phased studies
3(60.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

33.3%

1 of 3 finished

Non-Completion Rate

66.7%

2 ended early

Currently Active

2

trials recruiting

Total Trials

5

all time

Status Distribution
Active(2)
Completed(1)
Terminated(2)

Detailed Status

Withdrawn2
Recruiting2
Completed1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
2
Success Rate
100.0%
Most Advanced
Phase 1

Trials by Phase

Phase 12 (40.0%)
N/A3 (60.0%)

Trials by Status

withdrawn240%
recruiting240%
completed120%

Recent Activity

2 active trials
Showing 5 of 5
recruitingnot_applicable

Induction Chemotherapy Response-Guided Radiation for EBV-Associated Nasopharyngeal Carcinoma

NCT06682442
withdrawnphase_1

N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer

NCT07217496
recruitingphase_1

CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma

NCT07340853
withdrawnnot_applicable

Transcatheter Arterial Embolization in Patients With Mild to Moderate Osteoarthritis

NCT05013970
completednot_applicable

Femoral Lengthening Might Impair Physical Function and Lead to Structural Changes in Adjacent Joints

NCT03966573

Clinical Trials (5)

Showing 5 of 5 trials
NCT06682442Not Applicable

Induction Chemotherapy Response-Guided Radiation for EBV-Associated Nasopharyngeal Carcinoma

Recruiting
NCT07217496Phase 1

N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer

Withdrawn
NCT07340853Phase 1

CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma

Recruiting
NCT05013970Not Applicable

Transcatheter Arterial Embolization in Patients With Mild to Moderate Osteoarthritis

Withdrawn
NCT03966573Not Applicable

Femoral Lengthening Might Impair Physical Function and Lead to Structural Changes in Adjacent Joints

Completed

All 5 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
5